projects in

NSW

A new approach to boosting resistance to fungal infection in cancer patients

Advancing CAR-T cell therapy for extracranial solid paediatric cancers

Creating the Next Generation in Radiotherapy Imaging with Carbon Nanotube Sources and Photon Counting Detectors

Defining the cellular determinants that drive dynamin inhibitor induced cell death and in vivo efficacy against glioblastoma

Defining the critical role of osteoclasts in multiple myeloma cell growth and activation in bone

Developing a Patient-Reported Symptom Index for Non-muscle Invasive Bladder Cancer

Developing a new blood-based screening test for bowel cancer

Developing a novel targeted therapy for treating chemotherapy-resistant leukaemia

Developing inhibitors of the LMO4 oncoprotein

EAGLE FM Study: EvaluAtion of Groin Lymphadenectomy Extent For metastatic Melanoma

Engineering childhood cancer for precision medicine

Exploiting a new epigenetic regulatory mechanism for sustaining leukaemia-initiating activity

Functional characterisation of the putative tumour suppressor gene MCC in colorectal cancer

Gene modified T cells expressing a chimeric antigen receptor for a kappa light chain antigen to treat multiple myeloma

HCC Outcomes mitigation and disease Prevention through Clinical Partnerships (HOPE)

Ibudilast as a treatment for chemotherapy-induced peripheral neuropathies and cognitive impairments

Improving our understanding of the oncogenic signalling-metabolism nexus to design better treatments for pancreatic cancer

Investigating a gene that helps neuroblastomas grow blood vessels and spread throughout the body

Investigating why a new brain cancer drug works in some patients but not others

Melanoma Genome Mapping

Melanoma Margins Trial: A Phase III, Multi-centre Randomised Controlled Trial

Monitoring a patient’s real-time response to a new immunotherapy

Novel Treatment Targets in Low-Grade Serous Ovarian Cancer

Pan-cancer assessment of sensitivity towards novel selective oncogenic JNK inhibitors

Predicting clinical response to breast cancer therapy – the immune signature approach

Preventing people with immune deficiencies from developing cancer

Preventing the outgrowth of cancers that spread to bone

Protein Biosignatures for Predicting Recurrence of Stage II Colorectal Cancer

Rational Targeting of the Hedgehog Pathway to Treat Osteosarcoma

Real-time dose monitoring for patient safety in radiation therapy.

Resolving prostate cancer: Elucidating the epigenetics of tumour microenvironment cells to advance understanding of disease aetiology and improve patient diagnosis

Reversing treatment resistance in ER+ breast cancer

Reversing treatment resistance in melanoma

Selective manipulation of tumour-stroma signalling as a novel precision medicine approach: targeting treatment resistance in pancreatic cancer

Switching off the spread of triple-negative breast cancer

Targeting Innate Chemoresistance in Lung Adenocarcinoma

Targeting aggressive cancers that use the Alternative Lengthening of Telomeres (ALT) mechanism

Targeting pancreatic cancer (PC) via anti-fibrotic NID2 therapy and Gemcitabine/Abraxane chemotherapy treatment: stratifying PC therapy

Testing drug combinations for pancreatic cancer

The Kay Stubbs Project Grant: Exploring and Exploiting the Epigenetic Basis of Endocrine Resistant Breast Cancer

The Robyn Trinder Project Grant: Starving cancer cells: Developing nutrient uptake inhibitors as prostate cancer therapeutics

Treating brain tumours by blocking cell division

Using artificial intelligence to enhance radiotherapy effectiveness

Using combination therapies to treat liver cancer

VERTU - Veliparib, Radiotherapy and Temozolomide trial in Unmethylated MGMT Glioblastoma

When the stakes are high: Psychological and behavioural impact of genomic testing for breast cancer risk

Help us to put an end to cancer